R / Pharma and R / Medicine, two new R Consortium sponsored conferences that appeared in 2018, are both grass roots, community-level manifestations of fundamental trends driving the growth of R. R / Pharma organized as an R Consortium working group by R users at several prominent pharmaceutical companies demonstrated that R has reached sufficient critical mass in Pharma to be recognized as a technology important enough to explore inter-company cooperation, while the addition of Genetech/Roche to R Consortium shows the commitment of upper level management to migrate from SAS to R. - At the other, non-corporate end of the spectrum, the R / Medicine conference was well attended by practicing clinicians coming to R, and in some cases statistics and data analysis, for the first time in order to move forward with the practice of data driven medicine. - In this talk, I will present some highlights from these conferences, and other related R Consortium initiatives, describe some of the R-based projects that illustrate the kind of work being done, and indicate what to expect this year.
This topic was automatically closed after 21 days. New replies are no longer allowed.
If you have a query related to it or one of the replies, start a new topic and refer back with a link.